AstraZeneca (NYSE:AZN) Rating Reiterated by Barclays

Barclays reaffirmed their overweight rating on shares of AstraZeneca (NYSE:AZN) in a report published on Wednesday morning, The Fly reports.

Several other brokerages also recently issued reports on AZN. Cowen lifted their target price on AstraZeneca from $55.00 to $60.00 in a research note on Wednesday, June 10th. Guggenheim reiterated a buy rating on shares of AstraZeneca in a research report on Friday, May 29th. FIG Partners initiated coverage on shares of AstraZeneca in a research report on Thursday, April 23rd. They set a reduce rating for the company. Argus lifted their price target on shares of AstraZeneca from $54.00 to $60.00 and gave the company a buy rating in a report on Wednesday, May 6th. Finally, SVB Leerink increased their price target on AstraZeneca from $60.00 to $65.00 and gave the company an outperform rating in a research note on Friday, May 29th. Four analysts have rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. AstraZeneca presently has an average rating of Hold and an average price target of $61.00.

Shares of AZN stock opened at $55.78 on Wednesday. The company has a debt-to-equity ratio of 1.32, a current ratio of 0.75 and a quick ratio of 0.57. AstraZeneca has a one year low of $36.15 and a one year high of $64.94. The company’s fifty day moving average price is $54.53 and its 200-day moving average price is $50.30. The company has a market capitalization of $146.39 billion, a price-to-earnings ratio of 67.20, a PEG ratio of 1.65 and a beta of 0.55.

AstraZeneca (NYSE:AZN) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.48 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.44 by $0.04. AstraZeneca had a return on equity of 37.83% and a net margin of 8.36%. The business had revenue of $6.28 billion during the quarter, compared to analyst estimates of $6.27 billion. During the same quarter in the prior year, the business posted $0.73 EPS. AstraZeneca’s revenue for the quarter was up 9.7% compared to the same quarter last year. Equities research analysts expect that AstraZeneca will post 2.04 earnings per share for the current fiscal year.

The firm also recently declared a semi-annual dividend, which will be paid on Monday, September 14th. Investors of record on Friday, August 14th will be issued a $0.45 dividend. This represents a dividend yield of 2.5%. The ex-dividend date of this dividend is Thursday, August 13th. AstraZeneca’s payout ratio is 106.29%.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AZN. Wellington Management Group LLP increased its stake in AstraZeneca by 3.3% during the first quarter. Wellington Management Group LLP now owns 67,358,391 shares of the company’s stock worth $3,008,227,000 after acquiring an additional 2,163,500 shares during the last quarter. Jennison Associates LLC boosted its holdings in shares of AstraZeneca by 5.9% in the 1st quarter. Jennison Associates LLC now owns 38,802,123 shares of the company’s stock worth $1,732,903,000 after purchasing an additional 2,148,165 shares during the period. Capital International Investors increased its position in shares of AstraZeneca by 23.4% during the 1st quarter. Capital International Investors now owns 28,325,620 shares of the company’s stock valued at $1,265,021,000 after purchasing an additional 5,375,926 shares during the last quarter. Fisher Asset Management LLC raised its holdings in AstraZeneca by 1.1% during the 1st quarter. Fisher Asset Management LLC now owns 16,556,574 shares of the company’s stock valued at $739,417,000 after buying an additional 185,866 shares during the period. Finally, Invesco Ltd. lifted its position in AstraZeneca by 24.2% in the first quarter. Invesco Ltd. now owns 10,826,008 shares of the company’s stock worth $483,490,000 after buying an additional 2,106,066 shares during the last quarter. Institutional investors own 16.84% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

See Also: What is a stock portfolio tracker?

The Fly

Analyst Recommendations for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.